A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17)
Background/Objectives: Anterior Gradient-2 (AGR2/PDIA17) is a member of the protein disulfide isomerase (PDI) family of oxidoreductases. AGR2 is up-regulated in several solid tumors, including pancreatic ductal adenocarcinoma (PDAC). Given the dire need for new therapeutic options for PDAC patients,...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Antibodies |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4468/13/4/101 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846106212604575744 |
|---|---|
| author | Reeder M. Robinson Leticia Reyes Benjamin N. Christopher Ravyn M. Duncan Rachel A. Burge Julie Siegel Patrick Nasarre Pingping Wang John P. O’Bryan G. Aaron Hobbs Nancy Klauber-DeMore Nathan G. Dolloff |
| author_facet | Reeder M. Robinson Leticia Reyes Benjamin N. Christopher Ravyn M. Duncan Rachel A. Burge Julie Siegel Patrick Nasarre Pingping Wang John P. O’Bryan G. Aaron Hobbs Nancy Klauber-DeMore Nathan G. Dolloff |
| author_sort | Reeder M. Robinson |
| collection | DOAJ |
| description | Background/Objectives: Anterior Gradient-2 (AGR2/PDIA17) is a member of the protein disulfide isomerase (PDI) family of oxidoreductases. AGR2 is up-regulated in several solid tumors, including pancreatic ductal adenocarcinoma (PDAC). Given the dire need for new therapeutic options for PDAC patients, we investigated the expression and function of AGR2 in PDAC and developed a novel series of affinity-matured AGR2-specific single-chain variable fragments (scFvs) and monoclonal antibodies. Results: We found that AGR2 was expressed in approximately 90% of PDAC but not normal pancreas biopsies, and the level of AGR2 expression correlated with increasing disease stage. AGR2 expression was inversely related to SMAD4 status in PDAC and colorectal cancer cell models and was secreted from cells into their media. In normal tissues, a high density of AGR2 was detected in the epithelium of cells in the digestive tract but was lacking in most other normal tissue systems. The addition of recombinant AGR2 to cell culture and genetic overexpression of AGR2 increased the adhesion, motility, and invasiveness of both human and mouse PDAC cells. Human phage display library screening led to the discovery of multiple AGR2-specific scFv clones that were affinity-matured to produce monoclonal antibody (MAb) clones with low picomolar binding affinity (S31R/A53F/Y). These high-affinity MAbs inhibited AGR2-mediated cell adhesion, migration, and binding to LYPD3, which is a putative cell surface binding partner of AGR2. Conclusions: Our study provides novel, high-affinity, fully human, anti-AGR2 MAbs that neutralize the pro-tumor effects of extracellular AGR2 in PDAC. |
| format | Article |
| id | doaj-art-79f14c497620428b8b8b69e9d5c8b50a |
| institution | Kabale University |
| issn | 2073-4468 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibodies |
| spelling | doaj-art-79f14c497620428b8b8b69e9d5c8b50a2024-12-27T14:06:32ZengMDPI AGAntibodies2073-44682024-12-0113410110.3390/antib13040101A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17)Reeder M. Robinson0Leticia Reyes1Benjamin N. Christopher2Ravyn M. Duncan3Rachel A. Burge4Julie Siegel5Patrick Nasarre6Pingping Wang7John P. O’Bryan8G. Aaron Hobbs9Nancy Klauber-DeMore10Nathan G. Dolloff11Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Surgery, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Surgery, Medical University of South Carolina, Charleston, SC 29425, USACreative Biolabs, Inc., Shirley, NY 11967, USADepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Surgery, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USABackground/Objectives: Anterior Gradient-2 (AGR2/PDIA17) is a member of the protein disulfide isomerase (PDI) family of oxidoreductases. AGR2 is up-regulated in several solid tumors, including pancreatic ductal adenocarcinoma (PDAC). Given the dire need for new therapeutic options for PDAC patients, we investigated the expression and function of AGR2 in PDAC and developed a novel series of affinity-matured AGR2-specific single-chain variable fragments (scFvs) and monoclonal antibodies. Results: We found that AGR2 was expressed in approximately 90% of PDAC but not normal pancreas biopsies, and the level of AGR2 expression correlated with increasing disease stage. AGR2 expression was inversely related to SMAD4 status in PDAC and colorectal cancer cell models and was secreted from cells into their media. In normal tissues, a high density of AGR2 was detected in the epithelium of cells in the digestive tract but was lacking in most other normal tissue systems. The addition of recombinant AGR2 to cell culture and genetic overexpression of AGR2 increased the adhesion, motility, and invasiveness of both human and mouse PDAC cells. Human phage display library screening led to the discovery of multiple AGR2-specific scFv clones that were affinity-matured to produce monoclonal antibody (MAb) clones with low picomolar binding affinity (S31R/A53F/Y). These high-affinity MAbs inhibited AGR2-mediated cell adhesion, migration, and binding to LYPD3, which is a putative cell surface binding partner of AGR2. Conclusions: Our study provides novel, high-affinity, fully human, anti-AGR2 MAbs that neutralize the pro-tumor effects of extracellular AGR2 in PDAC.https://www.mdpi.com/2073-4468/13/4/101AGR2PDIA17anterior gradient-2protein disulfide isomerasepancreatic cancerPDAC |
| spellingShingle | Reeder M. Robinson Leticia Reyes Benjamin N. Christopher Ravyn M. Duncan Rachel A. Burge Julie Siegel Patrick Nasarre Pingping Wang John P. O’Bryan G. Aaron Hobbs Nancy Klauber-DeMore Nathan G. Dolloff A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17) Antibodies AGR2 PDIA17 anterior gradient-2 protein disulfide isomerase pancreatic cancer PDAC |
| title | A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17) |
| title_full | A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17) |
| title_fullStr | A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17) |
| title_full_unstemmed | A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17) |
| title_short | A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17) |
| title_sort | high affinity monoclonal antibody against the pancreatic ductal adenocarcinoma target anterior gradient 2 agr2 pdia17 |
| topic | AGR2 PDIA17 anterior gradient-2 protein disulfide isomerase pancreatic cancer PDAC |
| url | https://www.mdpi.com/2073-4468/13/4/101 |
| work_keys_str_mv | AT reedermrobinson ahighaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT leticiareyes ahighaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT benjaminnchristopher ahighaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT ravynmduncan ahighaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT rachelaburge ahighaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT juliesiegel ahighaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT patricknasarre ahighaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT pingpingwang ahighaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT johnpobryan ahighaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT gaaronhobbs ahighaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT nancyklauberdemore ahighaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT nathangdolloff ahighaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT reedermrobinson highaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT leticiareyes highaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT benjaminnchristopher highaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT ravynmduncan highaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT rachelaburge highaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT juliesiegel highaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT patricknasarre highaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT pingpingwang highaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT johnpobryan highaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT gaaronhobbs highaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT nancyklauberdemore highaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 AT nathangdolloff highaffinitymonoclonalantibodyagainstthepancreaticductaladenocarcinomatargetanteriorgradient2agr2pdia17 |